Drugmaker Valeant Pharmaceuticals, a fast-growing Wall Street darling until its price-hiking business strategy made it a symbol of pharmaceutical company greed, said it's undergoing a restructuring as its new CEO attempts to turn it around and repair its tattered reputation.
The company has come under a harsh spotlight for repeatedly buying older medicines with limited competition and then jacking their prices up threefold or more, with no changes or improvements to the drugs.
Solid outlook from Valeant, promised changes, fire up shares
Aucun commentaire:
Enregistrer un commentaire